Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma
Study Information
Alliance Study ID: A051202
NCT Study ID (ClinicalTrials.gov): NCT01644799
Alliance Committee: Lymphoma
Disease or Cancer Type: Lymphoma
Alliance Study Chair: John P. Leonard, MD
Status: COMPLETED
Study Description
Biologic therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Idelalisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This phase I trial studies the side effects and the best dose of lenalidomide when giving together with idelalisib in treating patients with recurrent follicular lymphoma.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information